• Alembic Pharma reported a 3% quarter-on-quarter (QoQ) decline in its consolidated revenues for the quarter ended September (Q2FY22). On a year-on-year (YoY) basis, the same fell by 11%.
  • Its expenses for the quarter were down by 4% QoQ and up by 3% YoY.
  • While the company’s net profit was up 3% QoQ during Q2FY22, it decreased by 49% on a YoY basis.
  • The earnings per share (EPS) of Alembic Pharma stood at 8.6.

Alembic Pharma’s Financial Statements for Q2FY22:

(Rs, crores) Q2FY21 Q1FY22 Q2FY22 QoQ (%) YoY (%)
Total Income 1,460 1,328 1,295 -3% -11%
Total Expenses 1,062 1,145 1,094 -4% 3%
Profit before tax 398 183 200 10% -50%
Tax 73 34 40 16% -46%
Profit after tax 333 165 169 3% -49%
Earnings per share 17.2 8.4 8.6    

Data Source: BSE, Company announcements

Want to get more analysis on Indian listed companies? Open an account and get daily stock research updates from Kotak Securities.

The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

-->